Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Illinois Colorectal Screening Update | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IllinoisPolicy RPLAB071

    Colorectal Cancer Screening

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Illinois Policy RPLAB071 alerts

    Get alerted when Policy RPLAB071 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This reimbursement policy governs when colorectal cancer screening services may be reimbursable for asymptomatic individuals and identifies screening methods that are not reimbursable. Providers must submit accurate coding and documentation, subject to applicable plan documents, contracts, and claim review.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyColorectal Cancer Screening
    Policy CodePolicy RPLAB071
    Change TypeMaterial update
    Effective DateDecember 4, 2026
    Last ReviewSep 4, 2026
    Next Review DateN/A
    Key ActionSubmit claims using valid HIPAA-approved code combinations and applicable industry-standard coding guidelines.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added potential reimbursement for multi-target stool DNA and multi-target stool RNA screening once every three years for asymptomatic individuals ages 45 through 75.

    The policy added a nonreimbursement rule when a different approved multi-target stool-based test is used within three years after a prior multi-target stool-based test.

    Procedure code 0421U was added to the policy's code list.

    Procedure code 0500T was removed from the policy's code list.

    45-75 yearsAge range for potentially reimbursable screening
    Annual

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FIT or gFOBT frequency
    Every 3 yearsApproved multi-target stool DNA or RNA frequency
    Over age 75Average-risk asymptomatic screening not reimbursable
    4 techniquesNonreimbursable techniques or test categories

    Colorectal Cancer Screening Coverage

    Potentially Reimbursable Screening

    Potentially reimbursable for asymptomatic individuals ages 45 to 75 when the applicable screening method and interval below are met:

    ONE of the following

    • ALL of the following

      • Individual is asymptomatic and 45 to 75 years of age
      • Annual colorectal cancer screening with a fecal immunochemical test (FIT), preferred, or a guaiac fecal occult blood test (gFOBT)
    • ALL of the following

      • Individual is asymptomatic and 45 to 75 years of age
      • Screening once every three years with a multi-target stool DNA (mt-sDNA)-based test, such as Cologuard™ or Cologuard Plus™, or a multi-target stool RNA (mt-sRNA)-based test, such as ColoSense™

    Nonreimbursable Screening

    Colorectal cancer screening is not reimbursable under any of the following circumstances:

    ANY of the following

    • For an asymptomatic individual ages 45 to 75, a different approved multi-target stool-based test is used when a multi-target stool-based test has already been performed within the last three years
    • Methylated Septin 9 (ColoVantage) is used for colorectal cancer screening
    • The individual is an average-risk, asymptomatic person over 75 years of age
    • Screening for anal cytologic abnormalities, including an anal Pap smear
    • Screening for anal HPV infection

    Covered and Nonreimbursable Screening Codes

    Fecal occult blood screening codesCPTCovered
    82270Occult blood feces
    82274Assay test for blood, fecal
    Multi-target stool-based colorectal screening codesmixedCovered
    81528Oncology colorectal screening
    0421UOncology colorectal screening, single-amplification RNA
    Methylated Septin 9 screening, including ColoVantageCPTNot Covered
    81327SEPT9 gene promoter methylation analysis
    Anal HPV and anal cytologic abnormality screeningCPTNot Covered
    87624HPV high-risk type, pooled result
    87625HPV types 16 and 18 only
    87626HPV separate high-risk type and pooled result
    88112Cytopathology cell enhancement technique
    Cell-free DNA colorectal cancer screeningmixedNot Covered
    0464UOncology colorectal screening, quantitative DNA markers
    0537UOncology colorectal cancer cell-free DNA greater than 2500 DMR
    Age eligibility
    Eligible populationAsymptomatic individuals ages 45 through 75
    FIT or gFOBT frequency
    Screening frequencyAnnual
    Multi-target stool DNA or RNA frequency
    Screening frequencyOnce every three years

    Documentation, Coding, and Claim Review

    Documentation Required

    Documentation Requirements

    Providers are responsible for submitting accurate documentation of the services performed and should submit any additional documentation requested.

    Billing Rule

    Accurate Claim Coding

    Submit claims using valid code combinations from HIPAA-approved code sets and follow applicable industry-standard coding guidelines.

    • Uniform Billing Editor, AMA CPT Assistant, CPT, HCPCS, ICD-10-CM, and ICD-10-PCS guidelines
    • National Drug Codes, Diagnosis Related Group guidelines, CMS National Correct Coding Initiative Policy Manual, CCI table edits, and other CMS guidelines
    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyColorectal Cancer Screening
    Policy CodePolicy RPLAB071
    Change TypeMaterial update
    Effective DateDecember 4, 2026
    Last ReviewSep 4, 2026
    Next Review DateN/A
    Key ActionSubmit claims using valid HIPAA-approved code combinations and applicable industry-standard coding guidelines.
    SourceLink
    On This Page
    Colorectal Cancer Screening CoverageCovered and Nonreimbursable Screening CodesDocumentation, Coding, and Claim Review
    Screening using cell-free DNA techniques, such as Guardant Shield™
    Repeat multi-target stool testing
    Repeat testing ruleA different approved multi-target stool-based test is not reimbursable when another multi-target stool-based test was performed within the prior three years
    Screening over age 75
    Reimbursement statusNot reimbursable for average-risk asymptomatic individuals over age 75
    Denial Risk

    Claim Review and Denial Risk

    Claims are subject to code-edit protocols and claim review, including review of benefit coverage terms, provider contract language, medical policies, reimbursement policies, and coding software logic.

    • Inaccurate coding, documentation, coverage limitations, contract terms, or applicable policy requirements may result in claim denial or nonpayment
    Note

    Product-Specific Coverage Review

    Review the applicable Plan documents before rendering services and submitting claims. Lab management reimbursement criteria do not necessarily apply uniformly to every product, and Plan documents or provider contracts govern if they conflict with this reimbursement policy.

    • Review Certificates of Health Care Benefits, Benefit Booklets, Summary Plan Descriptions, and other applicable coverage documents
    • Confirm eligible coverage for the specific member product and services rendered